These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 27726953)

  • 1. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
    Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
    Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
    Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
    Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis.
    Shigematsu Y; Inamura K; Yamamoto N; Mise Y; Saiura A; Ishikawa Y; Takahashi S; Kanda H
    BMC Cancer; 2018 Oct; 18(1):980. PubMed ID: 30326864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
    Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
    Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer.
    Xu W; Zhu Y; Shen W; Ding W; Wu T; Guo Y; Chen X; Zhou M; Chen Y; Cui L; Du P
    J Int Med Res; 2019 May; 47(5):1829-1842. PubMed ID: 30616445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
    Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
    Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of CDX2 immunoexpression in poorly differentiated clusters of colorectal carcinoma.
    Reggiani Bonetti L; Lionti S; Vitarelli E; Barresi V
    Virchows Arch; 2017 Dec; 471(6):731-741. PubMed ID: 28819729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
    Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
    Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
    Lundberg IV; Edin S; Eklöf V; Öberg Å; Palmqvist R; Wikberg ML
    BMC Cancer; 2016 Jul; 16():471. PubMed ID: 27411517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
    Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
    N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of CDX2 Expression With Survival in Early Colorectal Cancer: A Systematic Review and Meta-analysis.
    Tomasello G; Barni S; Turati L; Ghidini M; Pezzica E; Passalacqua R; Petrelli F
    Clin Colorectal Cancer; 2018 Jun; 17(2):97-103. PubMed ID: 29519711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study.
    Chen KH; Shao YY; Chen HM; Lin YL; Lin ZZ; Lai MS; Cheng AL; Yeh KH
    BMC Cancer; 2016 May; 16():327. PubMed ID: 27221731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of tumor deposits on the prognosis and chemotherapy efficacy in stage III colorectal cancer patients with different lymph node status: A retrospective cohort study in China.
    Li X; An B; Zhao Q; Qi J; Wang W; Zhang D; Li Z; Qin C
    Int J Surg; 2018 Aug; 56():188-194. PubMed ID: 29936197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.
    Bae JM; Lee TH; Cho NY; Kim TY; Kang GH
    World J Gastroenterol; 2015 Feb; 21(5):1457-67. PubMed ID: 25663765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prognostic and Predictive Utility of CDX2 in Colorectal Cancer.
    Chan WY; Chua W; Wilkinson K; Epitakaduwa C; Mandaliya H; Descallar J; Roberts TL; Becker TM; Ng W; Lee CS; Lim SH
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer.
    Wong HL; Lee B; Field K; Lomax A; Tacey M; Shapiro J; McKendrick J; Zimet A; Yip D; Nott L; Jennens R; Richardson G; Tie J; Kosmider S; Parente P; Lim L; Cooray P; Tran B; Desai J; Wong R; Gibbs P
    Clin Colorectal Cancer; 2016 Jun; 15(2):e9-e15. PubMed ID: 26968236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical Resection of Primary Tumor in Asymptomatic or Minimally Symptomatic Patients With Stage IV Colorectal Cancer: A Canadian Province Experience.
    Ahmed S; Fields A; Pahwa P; Chandra-Kanthan S; Zaidi A; Le D; Haider K; Reeder B; Leis A
    Clin Colorectal Cancer; 2015 Dec; 14(4):e41-7. PubMed ID: 26140732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content - a short report.
    Sandberg TP; Sweere I; van Pelt GW; Putter H; Vermeulen L; Kuppen PJ; Tollenaar RAEM; Mesker WE
    Cell Oncol (Dordr); 2019 Jun; 42(3):397-403. PubMed ID: 30847807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDX2 Is a Prognostic Biomarker for Unresectable Metastatic Colorectal Cancer.
    Mukohyama J; Agawa K; Yamashita K; Matsuda T; Shinoda M; Itano O; Kakeji Y
    Anticancer Res; 2023 Aug; 43(8):3763-3767. PubMed ID: 37500172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.